Levetiracetam (LEV) is a pyrrolidine derivative antiepileptic medication used for the treatment of seizures in pediatric and adult patients. We report a case of probable LEV-induced aseptic meningitis in a 13-year-old girl. The patient received LEV for a generalized seizure disorder and presented with symptoms 5 days after medication initiation. Ten days after LEV initiation, the patient presented to the hospital for further management. During her hospital course, infectious etiologies were ruled out with clinical and diagnostic testing. Upon discontinuation of LEV, the patient's symptoms resolved. Although select antiepileptic medications have been associated with drug-induced aseptic meningitis (DIAM), to date, no reports have been published about DIAM following the administration of LEV. We describe and categorize the probability of DIAM in association with LEV, as observed in a patient case.
Drug-induced aseptic meningitis (DIAM) is a subtype of aseptic meningitis, a clinical syndrome of meningeal inflammation that cannot be attributed to a bacterial source. 1 Drug-induced aseptic meningitis can be associated with antiepileptic medications, particularly carbamazepine and lamotrigine, as documented in many case reports. [1] [2] [3] Drug-induced aseptic meningitis is thought to occur as a result of hypersensitivity that may be due to immune complex deposition, drug toxicity, or induction of autoantibodies. 2, 3 Levetiracetam (LEV) is a pyrrolidine derivative antiepileptic medication that exerts its effects by binding to synaptic vesicle protein 2A (SV2a) in the brain. 4, 5 Synaptic vesicle protein 2A is involved in exocytosis of synaptic vesicles. 6 By binding SV2a, LEV impedes neurotransmitter exocytosis that can block the SV2a protein from interacting with the actin cytoskeletal network. 6 Other postulated mechanisms of action include modulation of voltagegated K + channels and N-type high-voltage-activated Ca 2+ currents. [6] [7] [8] As of November 2017, LEV was approved by the U.S. Food and Drug Administration (FDA) for use as adjunctive therapy in these patients: partial onset seizures in children 1 month of age and older with epilepsy, myoclonic seizures in children 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. 9 Levetiracetam exhibits high oral bioavailability (96%) that facilitates a 1:1 transition from intravenous administration. 4, 9 In a study measuring the concentration of LEV in the medial temporal gyrus, it was found that LEV levels in the brain tissue are similar to corresponding levels in the serum. 10 Levetiracetam has many other favorable characteristics including greater tolerability as compared with other antiepileptic medications, minimal C A S E R E P O R T drug interactions, and little plasma protein binding (less than 10%). 4, 5, 9, 11 Creatinine clearance is correlated with the clearance of LEV that affects dosing in renal impairment; however, hepatic impairment does not affect the clearance of LEV. 9 Reported adverse reactions in pediatric patients with 5% or greater incidence, as compared with placebo, include fatigue, aggression, nasal congestion, decreased appetite, and irritability. 9, 11, 12 No published studies have documented the development of DIAM following LEV administration. This case report describes the idiopathic presentation of aseptic meningitis in a patient previously receiving LEV.
Patient Case
A 13-year-old obese 64.7-kg Hispanic girl presented with progressive headache and altered mental status. Ten days before the current admission, she reported sharp frontal headaches and then had a witnessed generalized tonicclonic seizure; she fell twice, and, with the second fall, had generalized convulsions lasting 3 minutes followed by unresponsiveness for~7 minutes. Magnetic resonance imaging (MRI) of the brain with gadolinium performed at that time was normal. Based on electroencephalogram findings of bilateral, symmetric, synchronous, and predominantly frontal spike and wave activity, she was diagnosed with a generalized seizure disorder. Levetiracetam 250 mg orally 3 times daily was initiated, and she was discharged home. After treatment initiation with LEV, the patient did not have any additional seizures.
Five days after her previous admission, the intensity and frequency of the patient's headaches increased; the headaches now awakened her from sleep, with associated vomiting and photophobia. On the day of the current admission, by parental report, the patient appeared to be confused. She had no further clinically apparent seizures. She did not have fever, vision changes, rashes, neck stiffness, focal neurologic findings, or recent antecedent infections. She reported no administered medications other than LEV, no known allergies, and an up-to-date immunization record. She did not have relevant travel history, tuberculosis exposures, sexual activity, or known insect bites. Additionally, she did not have a medical history or family history of autoimmune disease or migraine.
On physical examination, she was noted to have papilledema and photophobia with no meningismus, neck stiffness, vision changes, or focal neurologic findings. Significantly, papilledema was not present at the time of her initial presentation with new-onset seizures. Cerebrospinal fluid (CSF) findings (Table 1) revealed a markedly elevated opening pressure, elevated total protein, and elevated white blood cell count with lymphocytic predominance. A comparative serum glucose was not available at the time of lumbar puncture to assess the presence of hypoglycorrhachia, although CSF glucose was likely low. Acyclovir, ceftriaxone, and vancomycin were initiated as empirical antimicrobial therapy for common infectious pathogens.
The level of LEV on the day of admission was 8 lg/ml, below the reference range of 12.0-46.0 lg/ml. Meningitis panel by polymerase chain reaction was negative for Escherichia coli K1, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae, cytomegalovirus, enterovirus, herpes simplex virus 1, herpes simplex virus 2, human herpesvirus 6, human parechovirus, varicella zoster virus, and Cryptococcus neoformans/gattii. Magnetic resonance imaging of the brain with gadolinium now showed elevated signal in the sulci over the cerebellum and portions of the cerebral hemispheres, consistent with meningitis, with no evidence of herniation, hydrocephalus, or arachnoiditis. Although the On hospital day 2, the patient's clinical status worsened, with uncontrollable headaches and elevated blood pressure to 150/100 mmHg. At this time, an external ventricular drain (EVD) was placed and dexamethasone was initiated. On hospital day 3, acyclovir was discontinued when the herpes simplex virus was clinically and diagnostically excluded as the cause of her symptoms. Levetiracetam was also discontinued at this time, due to the suspicion of possible DIAM. Seizure control was not altered after discontinuation of LEV, and no additional antiepileptic drugs were initiated. By hospital day 4, her headaches and hypertension had resolved, and her EVD was removed. Bacterial blood, urine, and CSF cultures were negative, so ceftriaxone and vancomycin were discontinued. The patient was discharged home on hospital day 9, with instructions to discontinue LEV and follow up with ophthalmology and neurology as an outpatient. All CSF, serum, and urine studies were returned negative (Table 2) .
Upon immediate discharge, the patient had no more episodes of seizure activity. Approximately 2 months after discharge, she presented with her second witnessed generalized tonic-clonic event lasting 2 minutes. She was initially started on valproic acid 250 mg extended release orally every 12 hours for 1 day and then switched to topiramate 25 mg orally twice daily and discharged home on topiramate.
Discussion
Levetiracetam use continues to increase in the pediatric population due to its favorable pharmacokinetic and pharmacodynamic profile. A recent meta-analysis of 13 randomized controlled trials found that LEV has comparable efficacy and tolerability compared with other antiepileptic drugs. 13 This meta-analysis noted a lower incidence of side effects with LEV; however, this difference was not statistically significant. The most frequently reported adverse events associated with LEV were classified as mild and transient. In published studies evaluating LEV, premature discontinuation due to adverse effects was infrequently reported and not attributed to DIAM. [12] [13] [14] [15] [16] Drug-induced aseptic meningitis was reported to occur with other antiepileptic medications, most commonly carbamazepine and lamotrigine. [1] [2] [3] In these reports, the episodes resolved quickly after discontinuation of the offending medication, and in cases in which the medication was restarted, episodes recurred and were often more severe. 1, 3, [17] [18] [19] Further research is warranted to identify the exact mechanism of DIAM.
The Naranjo Adverse Drug Reaction Probability Scale was used to evaluate the drug reaction described in this case report. 20 We concluded that LEV was a probable cause (score 6, Table 3 ) of idiopathic meningitis in this patient. Similar to previously reported antiepilepticrelated DIAM events, symptoms presented as early as 5 days after LEV initiation and resolved upon discontinuation. Treatment measures including steroid initiation and EVD placement may have contributed to the improvement in symptoms, although no alternative causes of meningitis were identified. The association of LEV and DIAM in this patient could be supported with reinitiation of the medication; however, that might result in unnecessary harm. The adverse event was reported internally as well as to the FDA MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
Conclusion
Drug-induced aseptic meningitis is a subtype of aseptic meningitis that was reported to occur with antiepileptic medications. 1 The association between LEV and DIAM was not previously reported in any published studies, case series, or case reports. Clinicians should be aware that DIAM is a possible adverse event associated with antiepileptic medications. Further reports are needed to confirm the probable association of LEV and DIAM, as described in this patient case. Are there previous conclusive reports on this reaction? +1 0 0 0 Did the adverse event appear after the suspected drug was administered? +2 À1 0 +2 Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?
Did the adverse reaction reappear when the drug was readministered?
Are there alternative causes (other than the drug) that could on their own have caused the reaction?
Did the reaction reappear when a placebo was given? À1 +1 0 0 Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? The adverse drug reaction is assigned a probability category based on the total score: definite if score is ≥ 9, probable if score is 5-8, possible if score is 1-4, and doubtful if score is 0.
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